Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. The gene discussed is ACACA; the disease is metabolic dysfunction-associated steatotic liver disease.